Arenegyr: Phase II started

MolMed began an open-label, Italian Phase II trial (Study NGR005) of 0.8 or 45 µg/m 2 of IV Arenegyr every 3 weeks in combination with oxaliplatin and capecitabine in 24 patients. ...